Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Foghorn Therapeutics

NASDAQ: FHTX ↗$2.02 USD~$0.25B MCAP
#Oncology#Small Molecule Therapeutics

Clinical-stage biotechnology company pioneering medicines that correct abnormal gene expression by targeting the chromatin regulatory system, including the BAF complex, for the treatment of cancer.

Company Info

Sector:Biotechnology
Headquarters:Cambridge, Massachusetts, USA
Founded:2016
Website:foghorntx.com/

Clinical Development Pipeline

FHD-909

Target: SMARCA2 (BRM)
SMARCA4-mutant non-small cell lung cancer
Preclinical
Phase 1
Phase 2
Phase 3
Approved

FHD-286

Target: BRG1/BRM
Acute myeloid leukemia and other BRG1-mutant cancers
Preclinical
Phase 1
Phase 2
Phase 3
Approved

CBP/EP300 degraders

Target: CBP/EP300
Oncology
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Adrian Gottschalk

President and Chief Executive Officer

Careers & Job Openings

See all open roles

All
Cambridge, Massachusetts, USA
Apply Now →